This Article Abstract Full Text Full Text (PDF) Correction (v46,p565) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gurm, H. S. Search for Related Content PubMed PubMed Citation Articles by Gurm, H. S.

Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus

An Analysis From the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 Trial

Hitinder S. Gurm, MD^_*, Ian J. Sarembock, MD, Dean J. Kereiakes, MD, John J. Young, MD, Robert A. Harrington, MD^||, Neal Kleiman, MD^||, Frederick Feit, MD^¶, Kathy Wolski, MPH^_*, John A. Bittl, MD^#, Robert Wilcox, MD^_**, Eric J. Topol, MD^_*, A. Michael Lincoff, MD^_*,_* for the REPLACE-2 Investigators

^_* Cleveland Clinic Foundation, Cleveland, Ohio
University of Virginia Health Systems, Charlottesville, Virginia
The Lindner Center and The Ohio Heart Health Center, Cincinnati, Ohio
Duke Clinical Research Institute, Durham, North Carolina
^|| Methodist-DeBakey Heart Center and Baylor College of Medicine, Houston, Texas
^¶ New York University School of Medicine, New York, New York
^# Oscala Heart Institute, Munroe Regional Medical Center, Oscala, Florida
^_** University Hospital Nottingham, Nottingham, United Kingdom

View larger version (12K): [in a new window]   Figure 1 Survival of the cohort at one year based on diabetes status. Solid line = non-diabetic patients; dashed line = diabetic patients.

View larger version (27K): [in a new window]   Figure 2 Outcomes of diabetic and non-diabetic patients by randomization arm. CI = confidence interval; GP = glycoprotein; Hep = heparin; MI = myocardial infarction.

View larger version (10K): [in a new window]   Figure 3 Survival of the diabetic patients by randomization arm. Solid line = bivalirudin; dashed line = glycoprotein IIb/IIIa inhibitor. PCI = percutaneous coronary intervention.